Sugi Predict

Sugi Predict / Compounds / SCHEMBL26439260

SCHEMBL26439260

SCHEMBL26439260

CN(C)C(=O)C1(F)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ DDB1 Q16531 2/20 0.36
▸ CRBN Q96SW2 2/20 0.36
▸ NR1H2 P55055 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ EPHX2 P34913 1/20 0.35
▸ RECQL P46063 1/20 0.34
▸ EPHX1 P07099 1/20 0.34
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20521215 0.88 USP30 (0.53) USP30USP2SMN1; SMN2HPGDEPHX2
SCHEMBL19979245 0.86 USP30 (0.40) USP30USP2SMN1; SMN2DDB1CRBN
SCHEMBL34474447 0.81 USP2 (0.42) USP30USP2SMN1; SMN2DDB1CRBN
SCHEMBL14917424 0.81 USP2 (0.44) USP30USP2SMN1; SMN2NR1H2HPGD
SCHEMBL34473285 0.80 USP2 (0.41) USP30USP2SMN1; SMN2DDB1CRBN
SCHEMBL23925508 0.79 USP2 (0.43) USP30USP2SMN1; SMN2NR1H2HPGD
SCHEMBL18420280 0.79 USP2 (0.43) USP30USP2SMN1; SMN2NR1H2HPGD
SCHEMBL22152249 0.79 USP30 (0.36) USP30USP2SMN1; SMN2DDB1CRBN
SCHEMBL22156359 0.79 USP30 (0.36) USP30USP2SMN1; SMN2DDB1CRBN
SCHEMBL12384327 0.78 USP2 (0.48) USP2SMN1; SMN2NR1H2HPGDEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240382483-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION 2024-11-21 — — US disclosed
CN-117858872-A Heterocyclic EGFR inhibitors for the treatment of cancer 缆图药品公司 2024-04-09 — — CN disclosed
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-02 — — US disclosed
WO-2023066204-A1 SIK INHIBITOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海美悦生物科技发展有限公司 2023-04-27 — — WO disclosed
WO-2022271612-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION (US) 2022-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors ITGB1, ITGB2, ITGA1 USP30 4355/4885USP2 4111/4885SMN1; SMN2 2790/4885
US-20240382483-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER EGFR, ERBB2, ERBB4 USP30 3448/4885USP2 3450/4885SMN1; SMN2 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.